Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TOKYO--(BUSINESS WIRE)--R-Tech Ueno, Ltd. (JASDAQ:4573): This is to announce start of the patient enrollment of the first stage of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101(Note 1); hereafter RU-101 ophthalmic solution), which is being developed in our company, in US for the treatment of severe dry eye. We are currently developing RU-101 ophthalmic solution to treat severe dry eye for which no effective treatment has been established.
Help employers find you! Check out all the jobs and post your resume.
